Preclinical Studies of Anti-Obesity Therapeutics
InquiryOverview of Preclinical Studies of Anti-Obesity Therapeutics
In the context of increasingly severe global health challenges, obesity has become a public health issue that cannot be ignored. Protheragen focuses on the research of obesity diseases. Our services cover the entire chain of solutions from Targets for Developing Anti-Obesity Therapeutics and Anti-Obesity Therapy Development to preclinical studies of anti-obesity therapeutics. We are committed to bringing innovative solutions to obesity diseases through cutting-edge scientific research and rigorous technical processes.
Pioneering Preclinical Studies in Anti-Obesity Therapeutics: Paving the Way for a Healthier and Leaner Future
We focus on preclinical studies of anti-obesity therapeutics and provide a solid foundation for drug development by constructing accurate obesity models to simulate the pathological state of obesity. We use advanced pharmacodynamic technology to deeply evaluate the effect of drugs on improving obesity-related indicators. Pharmacokinetic study reveals the dynamic changes of drugs in the body and optimize the dosing regimen. Bioanalysis ensures the accurate quantification of drugs and their metabolites in biological samples. Safety assessment comprehensively evaluates the safety of drugs to ensure that their safety is fully verified before clinical trials. The comprehensive use of this series of technologies, processes, and methods provides strong support for the research and development of anti-obesity drugs.
Obesity Models
We build a variety of obesity animal models including diet-induced, genetic, and hormone-induced models according to client needs. We ensure the scientificity and reproducibility of experimental results by simulating the pathophysiological characteristics of human obesity. At the same time, we provide customized model optimization services to meet the specific needs of different drug candidates.
- Diet-induced obesity model: We simulate human obesity caused by poor eating habits by giving a high-calorie diet. This model reflects various complications of obesity, such as insulin resistance and dyslipidemia.
- Genetic obesity model: We use animal strains with specific gene mutations, such as ob/ob mice (lack of leptin receptors) or db/db mice (lack of leptin) to simulate obesity caused by genetic factors. These models help study the role of specific genes in the occurrence of obesity.
- Hormone-induced obesity model: We simulate obesity caused by endocrine disorders by injecting or administering specific hormones (such as glucocorticoids). This model is of great significance for studying the effects of hormones on fat metabolism.
In Vivo Obesity Models for Obesity Research
We offer in vivo Obesity models for obesity research through four distinct approaches: by methods, by genes, by factors, and by taxonomy. Each approach provides a tailored set of models to meet the diverse needs of obesity research, ensuring comprehensive and precise insights into obesity mechanisms.
By Methods
We specialize in providing comprehensive in vivo obesity models for obesity research, encompassing a suite of tailored services such as gene editing-based, hypothalamic injury-based, oophorectomy-based, and drug injection-based in vivo obesity model development. These services collectively offer a robust platform to advance obesity research through precise and physiologically relevant models.
By Genes
We offer a comprehensive suite of in vivo obesity models for obesity research, including custom single gene mutation, custom single gene editing, custom multi-gene mutation, custom transgenic, and custom chromosome replacement model services. These tailored services empower researchers to delve deeper into obesity-related mechanisms with precision and control.
By Factors
We provide a wide range of in vivo obesity models for obesity research, encompassing high fat-induced, high sugar-induced, protein-induced, other nutrient-induced, and chemical-induced obesity models. These models offer versatile platforms to simulate various dietary and chemical factors contributing to obesity, enabling researchers to conduct thorough investigations into obesity mechanisms.
By Taxonomy
We offer a diverse portfolio of in vivo obesity models for obesity research, including mammal obesity models such as dog, pig, mouse, rat, monkey, guinea pig, and rabbit, as well as non-mammal obesity models like drosophila melanogaster, nematode, and zebrafish. These models cater to a wide range of research needs, enabling comprehensive studies on obesity across various species.
In Vitro Cell Models for Obesity Research
We specialize in providing a comprehensive range of in vitro cell models for obesity research, encompassing 3T3-L1 preadipocytes, primary human adipocytes, mesenchymal stem cells, adipose-derived stem cells, brown and white fat cells, SGBS cells, hepatocytes, RAW 264.7 cells, C2C12 myoblasts, GT1-7 cells, and INS-1 cells. These cell models offer versatile platforms for studying obesity-related mechanisms and pathways, enabling researchers to gain deeper insights into the disease.
Pharmacodynamic Study of Anti-Obesity Therapeutics
We evaluate the improvement effects of anti-obesity drugs on key indicators such as weight loss, body fat percentage reduction, and metabolic rate improvement through strictly designed pharmacodynamic experiments. We use advanced bioinformatics tools and statistical analysis methods to ensure that the data is accurate and reliable, providing a scientific basis for further optimization of drug candidates.
Pharmacokinetic Study of Anti-Obesity Therapeutics
We study the absorption, distribution, metabolism, and excretion of drugs in the body, and evaluate key parameters such as drug bioavailability, half-life, and tissue distribution. We predict the drug's in vivo efficacy and provide an important reference for drug dosage optimization and dosing regimen design by building a pharmacokinetic/pharmacodynamic model.
Bioanalysis of Anti-Obesity Therapeutics
We use highly sensitive and specific analytical methods, such as liquid chromatography-tandem mass spectrometry (LC-MS/MS) and enzyme-linked immunosorbent assay (ELISA) to accurately quantify the concentrations of drugs and their metabolites in biological samples. We ensure the accuracy and reliability of the analytical results and provide strong support for drug safety assessment.
Safety Assessment of Anti-Obesity Therapeutics
We comprehensively evaluate the safety of anti-obesity drugs on animal models through toxicology studies, including acute toxicity, subchronic toxicity, genotoxicity, and reproductive toxicity. We use advanced toxicity evaluation technology and strict safety assessment standards to ensure that the safety of drugs is fully verified before clinical trials.
Workflow
We initiate projects by communicating with clients to clarify goals and needs, followed by target confirmation and drug design based on research. We then construct and optimize obesity models, conduct pharmacodynamic and pharmacokinetic studies, and perform bioanalysis and safety assessments. Finally, we organize data into detailed reports and provide project summaries with follow-up support for drug development.
Applications of Preclinical Studies of Anti-Obesity Therapeutics
- Drug safety assessment: In the preclinical research stage, scientists test the safety of anti-obesity drugs in a variety of animal models (such as mice, rats, dogs, etc.).
- Pharmacodynamic studies: In preclinical studies, researchers evaluate the pharmacodynamic properties of anti-obesity drugs, that is, how the drugs affect body weight, fat distribution, appetite control, etc.
- Mechanism of action research: Preclinical research involves an in-depth exploration of the mechanism of action of anti-obesity drugs.
Advantages
- Professional scientific research team: We have a team of top scientists and senior R&D personnel who have deep expertise and rich practical experience in the fields of obesity pathological mechanisms, drug target discovery, and drug design.
- Unique mechanism of action and innovative drug design: Our anti-obesity drug research and development projects focus on novel molecular mechanisms and targets, aiming to achieve safe and effective weight management by regulating human energy balance, improving fat metabolism, or enhancing satiety.
- Strict experimental design and quality control: In the preclinical studies stage, we use multiple control groups, repeated experiments, and cross-validation methods to comprehensively evaluate the efficacy, safety, and pharmacokinetic properties of candidate drugs.
Publication
Published: 2018
Journal: Pharmacological Reviews
IF: 21.1
Results: The authors discuss the preclinical studies of anti-obesity therapeutics, highlighting the diverse strategies and mechanisms explored to counteract obesity. They provide an overview of various pharmacological targets and agents, such as those affecting appetite regulation, energy expenditure, and lipid metabolism. The review also emphasizes the importance of animal models in evaluating the efficacy and safety of potential treatments. By summarizing findings from multiple studies, the authors underscore the complexity of obesity and the necessity for multifaceted therapeutic approaches.
Fig.1 Schematic of the glucagon-like peptide 1 (GLP-1) derivatives approved by the Food and Drug Administration (FDA) for the treatment of diabetes. (Müller, et al., 2018)
Frequently Asked Questions
What aspects of the evaluation are mainly focused on during the preclinical research stage?
During the preclinical research stage, we mainly focus on the following aspects of evaluation.
- The efficacy evaluation of the drug. This includes the verification of the drug's effects in reducing body weight and improving body fat distribution through animal models.
- Safety evaluation. Strict toxicity tests, genetic toxicity tests, and reproductive toxicity tests are conducted to ensure that the drug is harmless to the human body.
- Pharmacokinetic properties. We evaluate the pharmacokinetic properties of the drug, that is, the absorption, distribution, metabolism, and excretion process of the drug in the body, to guide the subsequent clinical trial design.
How to ensure the accuracy and reliability of preclinical research results?
We ensure the accuracy and reliability of preclinical research results through the following measures: First, we strictly abide by internationally recognized experimental design and operation specifications, and adopt scientific and rigorous experimental methods and technical means. Second, we implement a strict quality control system to ensure the authenticity and traceability of experimental data. In addition, we conduct multiple groups of control experiments and cross-validation to reduce errors. Finally, our research team regularly communicates with global peers and accepts expert reviews to ensure the scientificity and authority of the research results.
Protheragen has always been committed to providing effective research solutions for obesity with a scientific, rigorous, innovative, and pragmatic attitude. We look forward to working with more partners to jointly promote the development of anti-obesity drugs. Please feel free to contact us for more details if you are interested in our preclinical studies of anti-obesity therapeutics!
Reference
- Müller, T.D.; et al. Anti-obesity therapy: from rainbow pills to polyagonists. Pharmacological reviews. 2018, 70(4): 712-746.
All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.